Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349440 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT00349440 is a Phase 4 study that has completed, run by Innovative Medical. The registered enrollment target is 93 participants.
The verdict
NCT00349440, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).
Interventions
- DRUG Cyclosporine, Refresh Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349440
The ClinicalTrials.gov registry entry for NCT00349440 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclosporine, Refresh Plus is the first listed.
NCT00349440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349440 about?
NCT00349440 is a clinical study titled "Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy". The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).
What is the current status of trial NCT00349440?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2006-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00349440?
The interventions under investigation include: Cyclosporine, Refresh Plus (DRUG).
Who is sponsoring clinical trial NCT00349440?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.